



Research Article

EVALUATION OF EFFLUX PUMP ACTIVITY AND BIOFILM FORMATION IN MULTIDRUG RESISTANT *KLEBSIELLA PNEUMONIAE* ISOLATES IN TANTA, EGYPT

Tarek El-Said El-Banna, Fatma Ibrahim Sonbol, Heba M. El-Dawy*, Lamiaa A. Al-Madboly

Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Tanta University, Tanta, Egypt

*Corresponding Author Email: hebaeldawy22@gmail.com

Article Received on: 24/02/21 Approved for publication: 31/03/21

DOI: 10.7897/2230-8407.1203123

ABSTRACT

Nosocomial and community acquired infections that caused by multidrug-resistant (MDR) *Klebsiella pneumoniae* isolates are widespread recently resulting in high morbidity and mortality due to limited number of treatment options with effective antibiotics. The aim of this study is to evaluate the antibiotic resistance profile, biofilm formation and efflux pump activity of MDR *K. pneumoniae* isolates collected from different hospitals in Tanta, Egypt. A total of 70 *K. pneumoniae* isolates characterized by standard biochemical tests and confirmed by MALDI-TOF/MS were screened for antibiotic susceptibility, efflux pump activity and biofilm formation. Isolates displayed high resistance to penicillins, cephalosporins, trimethoprim-sulfamethoxazole and the majority of tested fluoro-/quinolones and decreased resistance to imipenem, amikacin, chloramphenicol, tigecycline and colistin. Out of 70 *K. pneumoniae* isolates, 2 isolates exhibited Pan Drug-Resistance (PDR) profile while 57 (81.4%) and 11 (15.7%) exhibited MDR and Extensively drug-resistance (XDR) profiles, respectively. Sixty-four (91.4%) isolates exhibited efflux pump activity while all tested isolates had the ability to form biofilm with varied degrees as 40 (57.1%), 26 (37.1%), and 4 (5.7%) isolates were strong, moderate and weak biofilm producers, respectively. Also, a strong relation between efflux pump activity and biofilm formation per isolate was detected. In conclusion, Multidrug resistance, biofilm formation and efflux pump capabilities in *K. pneumoniae* have serious public health implications in the management and control of infections caused by this bacterium. Therefore, a multifaceted approach and precise planning are recommended in controlling these infections.

KEY WORDS: *Klebsiella pneumoniae*; Efflux; Biofilm; Antibiotic resistance

INTRODUCTION

Klebsiella pneumoniae is a Gram-negative, rod-shaped, nonmotile, encapsulated member of the family Enterobacteriaceae¹. *K. pneumoniae* has become an important healthcare-associated pathogen, causing about 14–20% of the community-acquired and nosocomial infections in the last two decades². With the emergence of hypervirulent and antibiotic resistant *K. pneumoniae* strains, their caused infections lead to high morbidity and mortality most frequently in high-risk individuals including immunosuppressed, neonates and the elderly^{3,4}. The increase in multidrug-resistant (MDR) *K. pneumoniae* in recent years is primarily resulted from the irrational use of antibiotics in treatment and prevention of infections caused by this bacterium⁵. There are several mechanisms of antibiotic resistance and creating MDR *K. pneumoniae* isolates including efflux pumps and biofilm formation⁶. Efflux pumps are protein-based structure that extrude the antibiotics from within cells that possess them in an energy dependent manner⁷. Biofilm is an aggregate of microorganisms in which cells are embedded in a matrix of extracellular polymeric substances (EPS). It has been associated with antibiotic resistance and persistence observed in several pathogenic bacteria including *K. pneumoniae* and their prevalence has been shown to be a major contributor to a number of distinct nosocomial infections that are difficult to be treated^{8,9}. Hence this study aimed at evaluating the efflux pump activity, biofilm formation and antibiotic resistance profile of *K. pneumoniae* isolates recovered from clinical samples in Tanta, Egypt.

MATERIALS AND METHODS

Ethics statement

All experiments were conducted in compliance with the ethical standards. The experimental protocols and consent forms were revised and accepted by the Research Ethics Committee, Faculty of Pharmacy, Tanta University, Egypt.

Bacterial isolation and identification

A total of 70 *Klebsiella pneumoniae* isolates were recovered from different clinical specimens, including urine, sputum, wound pus, burn, stool and blood, from patients admitted to the Tanta University Hospital and the National Cancer Institute, Tanta University. These isolates were examined microscopically and identified using a panel of standard biochemical tests according to the methods suggested by MacFaddin¹⁰. Also, these isolates were further confirmed by culturing on chromogenic agar medium. Confirmation of identity was performed using MALDI-TOF/MS with score values > 1.9, following the manufacturer recommendations (Bruker Daltonics, Germany).

Antimicrobial susceptibility testing

Antimicrobial susceptibility of the recovered *K. pneumoniae* isolates to various antimicrobials was determined by Kirby-Bauer disc diffusion method except for tigecycline and colistin that was determined by broth microdilution method, and results were interpreted in accordance with the recommendations of Clinical and Laboratory Standards Institute (CLSI) and the European

Committee on Antimicrobial Susceptibility Testing (EUCAST) for tigecycline^{11,12}. The antimicrobials tested by disc diffusion method were ampicillin (10 µg), amoxicillin/ clavulanate (20/10 µg), piperacillin/tazobactam (100/10 µg), cefuroxime (30 µg), cephalixin (30 µg), cefotaxime (30 µg), ceftriaxone (30 µg), ceftazidime (30 µg), aztreonam (30 µg), imipenem (10 µg), nalidixic acid (30 µg), ciprofloxacin (5 µg), pefloxacin (5 µg), norfloxacin (10 µg), ofloxacin (5 µg), levofloxacin (5 µg), gatifloxacin (5 µg), amikacin (30 µg), gentamycin (10 µg), trimethoprim-sulfamethoxazole (1.25/23.75 µg), chloramphenicol (30 µg), tetracycline (30 µg). All antibiotic discs were purchased from Oxoid, England. *K. pneumoniae* ATCC 13883 was used as a reference strain.

Multiple antibiotic resistance (MAR) index studies in *K. pneumoniae* isolates

The MAR index values for each isolate were calculated using the following formula:

MAR index for each isolate = Number of antibiotics to which the isolate was resistant/ Total number of antibiotics to which the isolate was exposed¹³.

Screening of efflux pump activity

Efflux pump activity of *K. pneumoniae* isolates was determined using the Ethidium Bromide (EtBr)-agar Cartwheel method¹⁴. Trypticase Soy agar (TSA) plates containing 0 mg/L, 0.25 mg/L, 0.5 mg/L, 1 mg/L, 1.5 mg/L, 2 mg/L and 2.5 mg/L concentrations of EtBr (Sigma, USA) were prepared fresh and kept protected from light. The tested bacterial cultures are prepared in liquid media, adjusted to 0.5 of a McFarland standards, swabbed on the EtBr-TSA plates forming a cartwheel pattern and incubated at 37°C for 16 h. After which bacterial culture were viewed under an UV trans-illuminator (Kowell, Spain) and the minimum concentration of EtBr (MC_{EtBr}) that produces fluorescence of the bacterial mass was recorded.

Screening of biofilm formation

The ability of isolates to form biofilm was determined by the microtitre plate technique¹⁵. For each isolate, 3 wells of a 96-well plastic tissue culture plate were filled with 180 µl of LB broth supplemented with 1% glucose and 20 µl of the overnight culture that diluted to a final optical density 600 (OD₆₀₀) equals 0.1. Sterile LB broth supplemented with 1% glucose was used as a negative control. After incubation at 37°C for 18 h, the content of each well was discarded, and wells were washed with phosphate buffered saline (PBS) for three times. Wells were dried for 1 h at 60°C, stained for 15 min with 180 µl of 2% crystal violet and washed again three times with PBS. Then, 180 µl of 33% (v/v) glacial acetic acid were added to each well to solubilize the dye bound to adherent cells and the optical density (OD) was measured at 570 nm using an ELISA auto-reader (Sunrise Tecan, Austria). The OD cut-off (OD_c) was described as three standard deviations above the mean OD of the negative control. The isolates were classified based on their adhesion capabilities into the following groups: non-biofilm producers (OD ≤ OD_c), weak biofilm producers (OD_c < OD ≤ 2 × OD_c), moderate biofilm producers (2 × OD_c < OD ≤ 4 × OD_c) and strong biofilm producers (4 × OD_c < OD).

Statistical analysis

The relationship between efflux activity and biofilm formation was conducted using chi-square test by SPSS software for Windows (version 20; SPSS Armonk, NY: IBM, USA). Statistical significance was defined as P value less than 0.05.

RESULTS AND DISCUSSION

The extensive use of antimicrobial agents has led to a high prevalence of MDR *K. pneumoniae* strains that caused several worldwide life-threatening hospital and community acquired infections¹⁶. In our study, multiple antibiotic (9-24) resistance was observed among the tested isolates. This phenomenon of multi-resistance was also observed in several other studies¹⁷⁻¹⁹. The frequency of resistant *K. pneumoniae* isolates was markedly high for 11 of the tested antibiotics as all (100%) isolates were resistant to ampicillin, cefuroxime, nalidixic acid and ciprofloxacin while 95.7%, 91.4%, 88.6%, 84.3%, 81.4%, 80% and 78.6% of the tested isolates were resistant to pefloxacin, norfloxacin, piperacillin/ tazobactam, trimethoprim-sulfamethoxazole, cephalixin, ofloxacin and cefotaxime, respectively (Fig. 1). In partial agreement with our results, Mohamed et al. (2018) in Egypt also reported a high incidence of resistance to nalidixic acid (100%), ciprofloxacin (100%), ampicillin (100%), cefuroxime (100%), piperacillin/ tazobactam (90%) and trimethoprim-sulfamethoxazole (80%) among biofilm producing *K. pneumoniae* isolates²⁰. Moreover, the frequency of resistant *K. pneumoniae* isolates was between 65% and 75% for six of used antibiotics (amoxicillin/clavulanate 74.2%, ceftriaxone 72.9%, ceftazidime 71.4%, aztreonam 67.1%, levofloxacin and gentamicin 65.7%). Comparable incidences of resistance to ceftriaxone (79%), ceftazidime (79%) or aztreonam (65.5%) were reported in another study in Egypt²¹. This observed high frequency of resistant isolates to penicillins and cephalosporins in our research and that of others could be due to the massive prescription and often misuse of these broad-spectrum antibiotics in Egypt for treatment of nosocomial and community acquired infections which often associated with extended- spectrum β- lactamase production. Also, relatively similar incidence (69.2%) of resistance to gentamicin were reported by Wassef et al. (2015)²².

The frequency of resistant *K. pneumoniae* isolates was less than 65% for tetracycline (60%), gatifloxacin (57.1%), amikacin and imipenem (44.3%), chloramphenicol (37.1%), tigecycline (20%) and colistin (2.9%) as shown in Fig. 1. Comparable results were reported by Ranjbar et al. (2019)²³ who recorded that 54% and 43.4% of their *K. pneumoniae* strains isolated from hospital-acquired infections were resistant to tetracycline and chloramphenicol, respectively. Increased chloramphenicol susceptibility than the past indicated that routine exposure of bacteria to newly developed antibiotics triggers a reversal of susceptibility to outdated antibiotics²⁴. A relatively similar (48.1%) incidence of resistance to imipenem has been also previously reported in China²⁵, this high incidence of resistance is considered an alarming notice as these antibiotics are the last line antibiotics for treatment of such bacterial pathogens. In Egypt, Helmy and Kashef, (2017)²⁶ reported amikacin incidence of resistance in 41% of *K. pneumoniae* isolates a finding that was nearly similar to that of our study (44.3%). We observed that our isolates were more resistant to gentamicin than toward the aminoglycoside amikacin, a finding that could be explained by the widespread use of gentamicin as an empirical therapy for the management of most of the nosocomial infections²⁷. Comparable incidence of resistance for tigecycline was reported by Heidary et al. (2017) who reported 15% incidence of resistance to tigecycline²⁸. This relatively lower incidence of tigecycline resistance recorded in our study and reported by others might indicate that tigecycline is potentially one of the most effective antimicrobial agents used in the treatment of *K. pneumoniae* infections.

Table 1: Relation between efflux pump and biofilm formation

Biofilm formation	Efflux pump							
	Positive		Negative		Total		Chi-square	
	N	%	N	%	N	%	X ²	P-value
Weak	1	1.6	3	50.0	4	5.7	26.566	<0.001*
Moderate	23	35.9	3	50.0	26	37.1		
Strong	40	62.5	0	0.0	40	57.1		
Total	64	100.0	6	100.0	70	100.0		




Figure 1: The percentage of resistant isolates to each antimicrobial agent

NA: Nalidixic acid, CIP: Ciprofloxacin, AMP: Ampicillin, CXM: Cefuroxime, PEF: Pefloxacin, NOR: Norfloxacin, TZP: Piperacillin/tazobactam, SXT: Trimethoprim/sulfamethoxazole, CL: Cefalexin, OFX: Ofloxacin, CTX: Cefotaxime, AMC: Amoxicillin/clavulanate, CRO: Ceftriaxone, FOX: Cefoxitin, ATM: Aztreonam, LEV: Levofloxacin, CN: Gentamicin, TET: Tetracycline, GAT: Gatifloxacin, IPM: Imipenem, AK: Amikacin, C: Chloramphenicol, TGC: Tigecycline and CT: Colistin sulfate

Although the incidence of colistin resistance was the lowest among our isolates, it is considered to be a threat alarm because colistin-resistant *Klebsiella* infections are potentially fatal. There are other studies in Egypt that recorded the high incidence of resistance to colistin as Tohamy et al. (2018)²⁹ and Zafer et al. (2019)³⁰ who reported 12.5% and 9.4% incidence of colistin resistance among their MDR *K. pneumoniae* isolates.

According to Mthembu (2008), if the MAR index value > 0.2 this means that such isolates were originated from environments where antibiotics were excessively used³¹. So, all of our tested *K. pneumoniae* isolates seemed to be originated from environments where antibiotics were overused as indicated by their high MAR index values (≥ 0.38).

As reported by Magiorakos et al. (2012), the isolate that have shown resistance to at least one agent in three or more antimicrobial classes is considered multidrug-resistant (MDR). The isolate that showed resistance to at least one agent in all but two or fewer antimicrobial classes is considered of extensively drug-resistance (XDR) profile. Pan drug-resistant (PDR) isolates are those showed resistance to all agents in all antimicrobial classes³². Accordingly, the majority (81.4%) of our isolates showed an MDR profile. The XDR and PDR profiles were detected in 15.7% and 2.9% of the tested isolates, respectively. Rates as high as 71% and 95.8% of MDR *K. pneumoniae* isolates were also observed in Egyptian studies performed by Wasfi et al. (2016)³³ and Kamel et al. (2018)¹⁸, respectively. Also, Taha & Omar, (2019)³⁴ detected PDR profile in 18.5 % of collected *Klebsiella* spp. isolates. This high rate of antimicrobial resistance can be due to the lack of strict policies that regulate the antibiotic use in Egypt³⁵.

Several mechanisms have been introduced overtime by bacterial pathogens in preventing the action of antibiotics. Possessing active efflux pumps is considered one of such mechanisms that was detected in 64 (91.6%) of *K. pneumoniae* isolates that showed fluorescence at EtBr concentration ≥ 2 mg/L which considered to phenotypically exhibit efflux pump activity. Also, Akinpelu et al. (2020)³⁶ reported that all MDR *K. pneumoniae* have an efflux pump activity. Thus, it could be suggested that active efflux pump played an important role in the observed antibiotic resistance.

K. pneumoniae is known to form biofilm that increases its virulence and resistance to antibacterial treatments³⁷. In our study, all the tested isolates were biofilm formers but with varied degrees as 40 (57.1%), 26 (37.1%) and 4 (5.7%) were classified into strong, moderate and weak biofilm formers (Table 1). Also, the study reported by Vuotto et al. (2017) found that 100% of their *K. pneumoniae* isolates were biofilm producers where 71%, 12.5% and 16.7% were strong, moderate and weak biofilm formers³⁸. In addition, our study reported a strong relation between efflux pump activity and biofilm formation per isolate which was highly significant ($P < 0.001$) as shown in Table 1. In agreement with our results, Reza et al. 2019 reported that the efflux pump activity and biofilm formation are connected to each other with a whole resulting effect of amplified antibiotic resistance⁹.

CONCLUSION

In this study, susceptibility testing of our isolates revealed a worrying trend of high prevalence of MDR *K. pneumoniae* strains. Moreover, the biofilm formation and efflux pump activities by such isolates may be a major barrier in treatment of *K. pneumoniae*-associated infections. Therefore, a multifaceted

approach and precise planning are recommended in controlling these infections. Our findings also support the idea that demonstrated the influential role of efflux pumps in bacterial biofilm formation and the increased antimicrobial resistance as we noticed that all strong biofilm formers *K. pneumoniae* isolates also exhibited active efflux pump activity. In addition, 3 of the four weak biofilm formers *K. pneumoniae* isolates did not phenotypically exhibit active efflux pump activity. Furthermore, two isolates (UR111 and SP70), recovered from urine and sputum, respectively, that were strong biofilm formers and exhibited efflux pump activity displayed pan resistance to all tested antimicrobials.

REFERENCES

- Podschun R, Ullmann U. *Klebsiella* spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. *Clinical Microbiology Reviews*. 1998 Oct;11(4):589–603.
- De Rosa FG, Corcione S, Cavallo R, Di Perri G, Bassetti M. Critical issues for *Klebsiella pneumoniae* KPC-carbapenemase producing *K. pneumoniae* infections: a critical agenda. *Future Microbiology*. 2015;10(2):283–94.
- Omeregbe R, Igbarum IO, Egbe CA, Ogefere HO. Urinary tract infection among neonates in Benin City, Nigeria. *Genomic Medicine, Biomarkers, and Health Sciences*. 2012 Dec;4(4):118–21.
- Li J, Huang ZY, Yu T, Tao XY, Hu YM, Wang HC, et al. Isolation and characterization of a sequence type 25 carbapenem-resistant hypervirulent *Klebsiella pneumoniae* from the mid-south region of China. *BMC Microbiology*. 2019 Sep;19(1):219.
- Fuzi M, Rodriguez Baño J, Toth A. Global evolution of pathogenic bacteria with extensive use of fluoroquinolone agents. *Frontiers in Microbiology*. 2020 Feb; 11:271.
- Yoon EJ, Oh Y, Jeong SH. Development of tigecycline resistance in carbapenemase-producing *Klebsiella pneumoniae* sequence type 147 via *AcrAB* overproduction mediated by replacement of the *ramA* promoter. *Annals of Laboratory Medicine*. 2020 Jan;40(1):15–20.
- Martins M, Viveiros M, Couto I, Costa SS, Pacheco T, Fanning S, et al. Identification of efflux pump-mediated multidrug-resistant bacteria by the ethidium bromide-agar cartwheel method. *In Vivo*. 2011 Mar-Apr;25(2):171–8.
- Dumar R, Baral R, Shrestha LB. Study of biofilm formation and antibiotic resistance pattern of gram-negative Bacilli among the clinical isolates at BPKIHS, Dharan. *BMC Research Notes*. 2019 Jan;12(1):38.
- Reza A, Sutton JM, Rahman KM. Effectiveness of efflux pump inhibitors as biofilm disruptors and resistance breakers in gram-negative (ESKAPEE) bacteria. *Antibiotics*. 2019 Nov;8(4):229.
- MacFaddin JF. *Biochemical tests for identification of medical bacteria* 3rd edition lippincott Williams and Williams. USA; 2000.
- CLSI. *Performance Standards for Antimicrobial Susceptibility Testing*. 29th ed. CLSI supplement M100S, editor. PA: Clinical and Laboratory Standards Institute Wayne; 2019.
- EUCAST. *The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 8.0, 2018*.
- Tambekar DH, Dhanorkar DV, Gulhane SR, Khandelwal VK, Dudhane MN. Antibacterial susceptibility of some urinary tract pathogens to commonly used antibiotics. *African Journal of Biotechnology*. 2006 Sep;5(17):1562–5.
- Martins M, McCusker MP, Viveiros M, Couto I, Fanning S, Pagès JM, et al. A Simple Method for Assessment of MDR Bacteria for Over-Expressed Efflux Pumps. *The Open Microbiology Journal*. 2013 Mar; 7:72–82.
- Donelli G, Vuotto C, Cardines R, Mastrantonio P. Biofilm-growing intestinal anaerobic bacteria. *FEMS Immunology & Medical Microbiology*. 2012 Jul;65(2):318–25.
- Ciccozzi M, Cella E, Lai A, De Florio L, Antonelli F, Fogolari M, et al. Phylogenetic Analysis of Multi-Drug Resistant *Klebsiella pneumoniae* Strains from Duodenoscope Biofilm: Microbiological Surveillance and Reprocessing Improvements for Infection Prevention. *Frontiers in Public Health*. 2019 Aug; 7:219.
- Khalil MA, Elgaml A, El-Mowafy M. Emergence of multidrug-resistant New Delhi metallo- β -lactamase-1-producing *Klebsiella pneumoniae* in Egypt. *Microbial Drug Resistance*. 2017 Jun;23(4):480–7.
- Kamel NA, El-Tayeb WN, El-Ansary MR, Mansour MT, Aboshanab KM. Phenotypic screening and molecular characterization of carbapenemase-producing Gram-negative bacilli recovered from febrile neutropenic pediatric cancer patients in Egypt. *PLoS One*. 2018 Aug;13(8): e0202119.
- Nirwati H, Sinanjung K, Fahrnis F, Wijaya F, Napitupulu S, Hati VP, et al. Biofilm formation and antibiotic resistance of *Klebsiella pneumoniae* isolated from clinical samples in a tertiary care hospital, Klaten, Indonesia. *BMC Proceedings*. 2019 Dec;13(11 Suppl 11):20.
- Mohamed SH, Mohamed MS, Khalil MS, Azmy M, Mabrouk MI. Combination of essential oil and ciprofloxacin to inhibit/eradicate biofilms in multidrug-resistant *Klebsiella pneumoniae*. *Journal of Applied Microbiology*. 2018 Jul;125(1):84–95.
- Mabrouk SS, Abdellatif GR, El-Ansary MR, Aboshanab KM, Ragab YM. Carbapenemase Producers Among Extensive Drug-Resistant Gram-Negative Pathogens Recovered from Febrile Neutrophilic Patients in Egypt. *Infection and Drug Resistance*. 2020 Sep;13: 3113–24.
- Wassef M, Abdelhaleim M, AbdulRahman E, Ghaith D. The Role of OmpK35, OmpK36 Porins, and Production of B-Lactamases on Imipenem Susceptibility in *Klebsiella pneumoniae* Clinical Isolates, Cairo, Egypt. *Microbial Drug Resistance*. 2015 Dec;21(6):577–80.
- Ranjbar R, Fatahian Kelishadrokhi A, Chehelgerdi M. Molecular characterization, serotypes and phenotypic and genotypic evaluation of antibiotic resistance of the *Klebsiella pneumoniae* strains isolated from different types of hospital-acquired infections. *Infection and Drug Resistance*. 2019 Mar; 12:603–11.
- Sood S. Chloramphenicol - A Potent Armament Against Multi-Drug Resistant (MDR) Gram Negative Bacilli? *Journal of Clinical and Diagnostic Research*. 2016 Feb;10(2): DC01–03.
- Li Y, Shen H, Zhu C, Yu Y. Carbapenem-resistant *Klebsiella pneumoniae* infections among ICU admission patients in Central China: prevalence and prediction model. *BioMed Research International*. 2019 Mar;2019: 9767313.
- Helmy OM, Kashef MT. Different phenotypic and molecular mechanisms associated with multidrug resistance in Gram-negative clinical isolates from Egypt. *Infection and Drug Resistance*. 2017 Dec; 10:479–98.
- El-Badawy MF, Tawakol WM, El-Far SW, Maghrabi IA, Al-Ghamdi SA, Mansy MS, et al. Molecular identification of aminoglycoside-modifying enzymes and plasmid-mediated quinolone resistance genes among *Klebsiella pneumoniae* clinical isolates recovered from Egyptian patients. *International Journal of Microbiology*. 2017; 2017:8050432.

28. Heidary M, Goudarzi H, Hashemi A, Eslami G, Goudarzi M, Chirani AS, et al. Prevalence of Quinolone Resistance Genes in *Klebsiella pneumoniae* Strains Isolated from Hospitalized Patients During 2013-2014. Archives of Pediatric Infectious Diseases. 2017;5(4): e38343
29. Tohamy ST, Aboshanab KM, El-Mahallawy HA, El-Ansary MR, Afifi SS. Prevalence of multidrug-resistant Gram-negative pathogens isolated from febrile neutropenic cancer patients with bloodstream infections in Egypt and new synergistic antibiotic combinations. Infection and Drug Resistance. 2018 May;11: 791–803.
30. Zafer MM, El-Mahallawy HA, Abdulhak A, Amin MA, Al-Agamy MH, Radwan HH. Emergence of colistin resistance in multidrug-resistant *Klebsiella pneumoniae* and *Escherichia coli* strains isolated from cancer patients. Annals of Clinical Microbiology and Antimicrobials. 2019 Dec;18(1):40
31. Mthembu MS. (2008). The usefulness of multiple antibiotic resistance (MAR) indexing technique in differentiating fecal coliform bacteria from different sources (Doctoral dissertation).
32. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection. 2012 Mar;18(3):268–81.
33. Wasfi R, Elkhatib WF, Ashour HM. Molecular typing and virulence analysis of multidrug resistant *Klebsiella pneumoniae* clinical isolates recovered from Egyptian hospitals. Scientific Reports. 2016 Dec;6(1):1-11.
34. Taha SA, Omar HH. Characterization of plasmid-mediated *qnrA* and *qnrB* genes among Enterobacteriaceae strains: quinolone resistance and ESBL production in Ismailia, Egypt. Egyptian Journal of Medical Human Genetics. 2019;20(1):26–32.
35. Daef EA, Elsherbiny NM. Clinical and microbiological profile of nosocomial infections in adult intensive care units at Assiut University hospitals, Egypt. Journal of American Science. 2012;8(12):1239–50.
36. Akinpelu S, Ajayi A, Smith SI, Adeleye AI. Efflux pump activity, biofilm formation and antibiotic resistance profile of *Klebsiella* spp. isolated from clinical samples at Lagos University Teaching Hospital. BMC Research Notes. 2020 May; 13(1):258.
37. Roy R, Tiwari M, Donelli G, Tiwari V. Strategies for combating bacterial biofilms: A focus on anti-biofilm agents and their mechanisms of action. Virulence. 2018 Jan;9(1):522–54.
38. Vuotto C, Longo F, Pascolini C, Donelli G, Balice MP, Libori MF, et al. Biofilm formation and antibiotic resistance in *Klebsiella pneumoniae* urinary strains. Journal of Applied Microbiology. 2017 Oct;123(4):1003–18.

Cite this article as:

Tarek El-Said El-Banna et al. Evaluation of efflux pump activity and biofilm formation in multidrug resistant *Klebsiella pneumoniae* isolates in Tanta, Egypt. Int. Res. J. Pharm. 2021;12(3):1-5.
<http://dx.doi.org/10.7897/2230-8407.1203123>

Source of support: Nil, Conflict of interest: None Declared

Disclaimer: IRJP is solely owned by Moksha Publishing House - A non-profit publishing house, dedicated to publishing quality research, while every effort has been taken to verify the accuracy of the content published in our Journal. IRJP cannot accept any responsibility or liability for the site content and articles published. The views expressed in articles by our contributing authors are not necessarily those of IRJP editor or editorial board members.